193 466

Cited 18 times in

Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.

DC Field Value Language
dc.contributor.author박윤아-
dc.contributor.author손승국-
dc.contributor.author이강영-
dc.date.accessioned2015-04-24T17:42:32Z-
dc.date.available2015-04-24T17:42:32Z-
dc.date.issued2009-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105917-
dc.description.abstractPURPOSE: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer. This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer. MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA. We calculated the cell death rate (CDR) by measuring intracellular ATP levels of drug-exposed cells and untreated controls. RESULTS: Interpretable results were available for 85.5% (118/138) of patients. The mean coefficient of variation for triplicate ATP measurements was 9.2%. The highest CDR was observed in irinotecan (34.0%) and the lowest CDR in etoposide (21.0%). Paclitaxel had the broadest range of CDR (0-86.7%) and 5-FU had the narrowest range of CDR (0-56.8%). The overall highest responsiveness was seen most prevalently in irinotecan (24.7%, 23/93 patients). Irinotecan had the greatest responsiveness in patients with well differentiated and moderately differentiated carcinoma. CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.-
dc.description.statementOfResponsibilityopen-
dc.format.extent697~703-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy*-
dc.subject.MESHAdenosine Triphosphate/metabolism*-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Agents/pharmacology*-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHColorectal Neoplasms/drug therapy*-
dc.subject.MESHDrug Screening Assays, Antitumor/methods*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrecision Medicine-
dc.subject.MESHTumor Cells, Cultured-
dc.titleHeterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학)-
dc.contributor.googleauthorJung Wook Huh-
dc.contributor.googleauthorYoon Ah Park-
dc.contributor.googleauthorKang Young Lee-
dc.contributor.googleauthorSeung-Kook Sohn-
dc.identifier.doi10.3349/ymj.2009.50.5.697-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01599-
dc.contributor.localIdA01978-
dc.contributor.localIdA02640-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid19881975-
dc.subject.keywordAdenosine triphosphate-
dc.subject.keywordchemotherapy response assay-
dc.subject.keywordcolorectal cancer-
dc.contributor.alternativeNamePark, Yoon Ah-
dc.contributor.alternativeNameSohn, Seung Kook-
dc.contributor.alternativeNameLee, Kang Young-
dc.contributor.affiliatedAuthorPark, Yoon Ah-
dc.contributor.affiliatedAuthorSohn, Seung Kook-
dc.contributor.affiliatedAuthorLee, Kang Young-
dc.citation.volume50-
dc.citation.number5-
dc.citation.startPage697-
dc.citation.endPage703-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.50(5) : 697-703, 2009-
dc.identifier.rimsid51438-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.